Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, PR China; National Center for Protein Sciences Beijing, State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 102206, PR China.
National Center for Protein Sciences Beijing, State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing 102206, PR China.
J Chromatogr A. 2023 Mar 29;1693:463882. doi: 10.1016/j.chroma.2023.463882. Epub 2023 Feb 21.
Exosomes have great potential as biomarker carriers for disease diagnosis and prognosis. In recent years, exosomal RNA (exoRNA) has become a promising candidate for the early diagnosis and prognosis of cancers, and its pathophysiological roles in various diseases have been revealed. For example, exosome-derived mRNAs, miRNAs, circRNAs, and lncRNAs function as signalling molecules to regulate tumour growth, angiogenesis, invasion, metastasis, and the response to chemotherapy. However, the isolation of exosomes and exoRNA with high quality and purity remains challenging due to the relatively small size of exosomes and the limited amount of RNA in exosomes. In this work, we developed a novel tandem enrichment method to isolate exoRNA from serum based on the specific interaction between titanium dioxide (TiO) and the phosphate groups on the lipid bilayer of exosomes and of the exoRNA. TiO-based RNA isolation was first demonstrated and optimized in HeLa cells. A total of 130.9 ± 8.34 µg of RNA was rapidly enriched from approximately 5 × 10 HeLa cells within 10 min. This was a 41.5% higher yield than that using a commercial Ultrapure RNA Kit. TiO-based tandem enrichment of exoRNA was then performed using human serum, obtaining 64.53±3.41 ng of exoRNA from 500 µL of human serum within 30 min. A total of 2,137,902 reads, including seven types of exoRNAs, were identified from the exosomes. This method is compatible with various downstream RNA processing techniques and does not use toxic or irritating reagents, such as phenol or chloroform, providing a simple, economical, rapid, and safe approach for exoRNA extraction from biological samples.
外泌体作为疾病诊断和预后的生物标志物载体具有巨大的潜力。近年来,外泌体 RNA(exoRNA)已成为癌症早期诊断和预后的有前途的候选物,其在各种疾病中的病理生理作用也已被揭示。例如,外泌体来源的 mRNAs、miRNAs、circRNAs 和 lncRNAs 作为信号分子发挥作用,调节肿瘤生长、血管生成、侵袭、转移和对化疗的反应。然而,由于外泌体的相对较小尺寸和外泌体中 RNA 的有限量,高质量和高纯度的外泌体和 exoRNA 的分离仍然具有挑战性。在这项工作中,我们开发了一种新颖的串联富集方法,基于二氧化钛 (TiO) 与外泌体和 exoRNA 脂质双层上的磷酸基团之间的特异性相互作用,从血清中分离 exoRNA。TiO 基 RNA 分离首先在 HeLa 细胞中进行了证明和优化。从大约 5×10 HeLa 细胞中,在 10 分钟内快速富集了 130.9±8.34µg 的 RNA,比使用商业 Ultrapure RNA 试剂盒的产量高 41.5%。然后使用人血清进行 TiO 基串联富集 exoRNA,在 30 分钟内从 500µL 人血清中获得 64.53±3.41ng 的 exoRNA。从外泌体中鉴定出总共 2,137,902 个读段,包括七种类型的 exoRNAs。该方法与各种下游 RNA 处理技术兼容,并且不使用有毒或刺激性试剂,如苯酚或氯仿,为从生物样品中提取 exoRNA 提供了一种简单、经济、快速和安全的方法。